Our data suggest that upregulation of membrane translocation of GLUT4, which is commonly impaired in both T1DM and T2DM, is a potential mechanism underlying carvacrol-mediated improvement in cardiac glucose utilization, simultaneously as its blood glucose-lowering effect, and attenuation of left ventricular function in both types of diabetes. This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.